ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Eur J Cancer · 2026-10-02

Secondary analysis of ARASENS in metastatic hormone-sensitive prostate cancer: darolutamide + ADT + docetaxel vs placebo + ADT + docetaxel added 6.3 months of Q-TWiST over 53 months (p<0.001; relative gain 16.0%), but time with grade 3/4 toxicity was longer (17.2 vs 11.3 months).

Secondary analysis
Maiorano et al. Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial
Urology · Prostate Cancer Prostatic Dis · 2026-06-20

Secondary analysis of 65 Black patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE trial: darolutamide plus ADT reduced risk of radiological progression or death by 49% vs placebo plus ADT, consistent with the overall trial.

Secondary analysisn = 65
Trinh et al. Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
Oncology · Eur J Cancer · 2026-06-12

Secondary analysis of the phase III ARASENS trial (n=1305, metastatic hormone-sensitive prostate cancer): darolutamide plus ADT and docetaxel vs placebo delayed mCRPC (HR 0.36) and pain progression (HR 0.79); pain interference/severity and HRQoL worsening were similar.

Secondary analysisn = 1,305
Fizazi et al. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial
Oncology · Lancet Oncol · 2026-04-09

Secondary analysis of the phase 3 ARANOTE trial (669 men with mHSPC): darolutamide plus ADT vs placebo delayed pain progression (HR 0.72) and deterioration in FACT-P quality of life (HR 0.76, exploratory); serious AEs 24% in both.

Secondary analysisn = 669
Morgans et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial
Urology · Prostate Cancer Prostatic Dis · 2026-02-12

Post hoc analysis of ARAMIS (1,509 patients with nmCRPC on ADT): metastatic progression occurred in 14% with darolutamide vs 29% with placebo, with similar sites. PSA <0.2 ng/ml was reached in 25.1% vs 0.5%, and reaching it was associated with less radiological progression.

Secondary analysisn = 1,509
Morgans et al. Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.